Komori
Tsubota Laboratory (4890) · RiskRestated

Risk of unexpected adverse effects from pharmaceuticals and medical devices

First written in FY2022. 3 of 4 entries say "Restated". Latest entry: FY2026.

4entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2022 – FY20262022: 120222023: 120232024: 120242025: 020252026: 12026
Same theme, other companies
Health Damage from Pharmaceuticals and Product Liability RiskA theme 58 companies write about · 67 as a headwind · 1 as a tailwind

The whole theme swung hardest in 2026: 6 of 20 companies on the "Worse" side.

36 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 58 companies compared. The sentences above are computed from all 58.
Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「Pharmaceuticals and medical devices may cause unexpected adverse effects from the clinical trial stage through to after launch, which could adversely affect confidence in the Company.」

    Restates the risk of unexpected adverse effects from the clinical trial stage through to after launch.
  2. FY2024RestatedAnnual report

    「Pharmaceuticals and medical devices may cause unexpected adverse effects from the clinical trial stage through to after launch,」

    Restates the risk of unexpected adverse effects from the clinical trial stage through to after launch.
  3. FY2023RestatedAnnual report

    「Pharmaceuticals and medical devices may cause unexpected adverse effects from the clinical trial stage through to after launch,」

    Continues to disclose the risk of unexpected adverse effects from the clinical trial stage through to after launch.
  4. FY2022First statedAnnual report

    「Pharmaceuticals and medical devices may cause unexpected adverse effects from the clinical trial stage through to after launch,」

    The likelihood of occurrence is described as low and the impact as high.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Tsubota Laboratory yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of unexpected adverse effects from pharmaceuticals and medical devices | Tsubota Laboratory Incorporated (4890) | Komori